John Wallbillich
Academic Rank
Assistant Professor
Office Address
4160 John R
HP07GO Suite 721
Detroit, MI 48201
Fax: 313-576-8988
Awards and Honors
GCC Superhero Award - 2019
Georgia Cancer Center, Medical College of Georgia
Augusta University, Augusta, Georgia
This award is given annually to clinical and clinical research staff at the Georgia Cancer Center, and is based primarily on patient nominations. I was one of several physicians, and the only surgeon, to receive this award in 2019.
Felix Rutledge Fellow - 2012
University of Texas MD Anderson Cancer Center
Department of Gynecologic Oncology, Houston, Texas
Competitive third-year audition rotation for residents intending to pursue subspecialty training in gynecologic oncology.
James B. Angell Scholar - 2004
University of Michigan, Ann Arbor, Michigan
Honor for receiving an “A” record for two or more consecutive terms as an undergraduate student.
John and Josephine Castiglione Scholarship in Medical Ethics University of Michigan, Ann Arbor, Michigan - 2003
Competitive scholarship with financial award for an undergraduate at the University of Michigan noted to show promise in the field of medical ethics.
Biomedical Science Summer Research Fellowship - 2002
Undergraduate Research Opportunity Program
University of Michigan, Ann Arbor, Michigan
Competitive mentored and funded research fellowship awarded to undergraduate students in University of Michigan’s Undergraduate Research Opportunity Program (UROP). Based on progress made during the fall and winter terms as a UROP student and judging of a grant application for a novel
research project.
University Honors (every term enrolled) 2000-2004
University of Michigan, Ann Arbor, Michigan
Honor for receiving a 3.5 grade point average or higher during a term as an undergraduate student.
Education
Doctor of Medicine - 2005-2009
University of Michigan Medical School
Ann Arbor, MI
B.S. in Biopsychology and Cognitive Science, with Distinction - 2000-2004
University of Michigan College of Literature, Science, and the Arts Ann Arbor, MI
Post Graduate Training
Women’s Reproductive Health Research Scholar - 2016-2019
Women’s Reproductive Health Research Program (NIH K12)
Medical College of Georgia, Augusta University
Augusta, GA
Fellowship in Gynecologic Oncology - 2013-2016
James Comprehensive Cancer Center
The Ohio State University, Columbus, OH
Residency in Obstetrics and Gynecology - 2009-2013
Memorial Hermann Hospital Program
University of Texas Health Science Center at Houston
Houston, TX
Professional Experience
Major professional societies
- Member, Mid-Atlantic Gynecologic Oncology Society - 2018-present
- Member, Society of Gynecologic Oncology - 2013-present
Publications
1. Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, Cohn DE, Selvendiran K. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene 2018 Jul;37(28):3806-3821. [PMID: 29636548]
2. Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner R, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K. STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube. Cancer Research 2018 Apr;78(7):1739-1750. [PMID: 29339537]
3. Cohn DE, Backes FJ, Wallbillich JJ, Bixel K, Crafton SM, Neff R, ElNaggar AC, Smith B, Suarez AA. Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecologic Oncology 2017 Mar;144(3)451-455. [PMID: 28161140]
4. Wallbillich JJ, Josyula S, Saini U, Zingarelli RA, Dorayappan KDP, Riley MK, Wanner RA, Cohn DE, Selvendiran K. High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer. PLOS ONE 2017 Jan 23;12(1):e0170318. [PMID: 28114390]
5. Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 2017 Jan 12;36(2):168-181. [PMID: 27292260]
6. Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic Oncology 2016 Jul;142(1):144-9. [PMID: 27106017]
7. Dorayappan KDP, Wallbillich JJ*, Cohn DC, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecologic Oncology 2016 Jul;142(1):199-205. [PMID: 27058839] *co-first authorship
8. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, Frumovitz M, Ramondetta LM, Schmeler KM. Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecologic Oncology 2013 Jun;129(3):513-6. [PMID: 23541795]
9. Wallbillich JJ, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz M, Brown J, Trimble CL, Schmeler KM. Vulvar Intraepithelial Neoplasia (VIN2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology 2012 Nov;127(2):312-5. [PMID: 22867736]
10. Wallbillich JJ, Nick AM, Ramirez PT, Watkins JL, Euscher ED, Schmeler KM. Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary. Gynecologic Oncology Case Reports 2012 Feb 13;2(2)58-60. [PMID: 24371617]
Published abstracts
1. Myers E, Tran LK*, Tran PM, Mysona D, Purohit S, Wallbillich JJ, She JX. Identifying genetic drivers of uterine serous carcinoma patient prognosis with regulatory network analysis. Cancer Research, Volume 79, Supplement 13, Pages 2459-2459.
2. Tran LK, Myers EK, Mysona DP, Tran PM, Lee W, Wallbillich JJ, Kleven D, Ghamande S, She JX. Predicting survival and improving treatment for uterine serous carcinoma patients using USC78, a genomic risk score. Cancer Research, Volume 79, Supplement 13, Pages 1704-1704.
3. Purohit S, Tran PMH, Tran LKH, Zhi W, Song X, Dun B, Ferris DG, Wallbillich JJ, Cummings RD, Wang PG, She JX. Anti-glycan antibodies as predictors of therapeutic outcome in cervical cancer patients.
Cancer Research, Volume 79, Supplement 13, Pages 2301-2301
4. Pyrzak A, Patel KB, Williams H, Coste H, Zhang LF, Sadek R, Wallbillich JJ, Ghamande S, Rungruang BJ. Clinical trial participation may improve survival in patients with advanced epithelial ovarian, fallopian, and peritoneal malignancies. Gynecologic Oncology, Volume 149, Supplement 1, June 2018, Pages 201-202.
5. Dorayappan KDP, Zingarelli RA, Hisey CL, Smith BQ, Wanner R, Saini U, Hansford D, Wallbillich JJ, She JX, Lester J, Karlan BY, Suarez A, Cohn DE, Karuppaiyah S. Evaluating exosome proteins as biomarkers for the early detection of high-grade serous ovarian cancer. Gynecologic Oncology, Volume 149, Supplement 1, June 2018, Page 71.
6. Patel KB, Pyrzak A, Williams H, Coste H, Zhang LF, Sadek R, Wallbillich JJ, Ghamande S, Rungruang BJ. Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. Gynecologic Oncology, Volume 149, Supplement 1, June 2018, Pages 4-5.
7. Dorayappan KDP, Wallbillich JJ, Saini U, Bixel K, Riley MK, Zingarelli RA, Wanner RA, Goodfellow PJ, Cohn DE, Selvendiran K. Hypoxia-facilitated exosomal release from ovarian cancer cells is regulated by STAT3 and is associated with increased metastatic tumor burden. Gynecologic Oncology, Volume 141, Supplement 1, June 2016, Page 66.
8. Saini U, Bixel K, Wallbillich JJ, Riley MK, Fowler J, Wanner R, Lester J, Karlan BY, Goodfellow PJ, Suarez A, Cohn DE and Selvendiran K. STAT3/PIAS3 as “early signature” gene pathways in the development of ovarian high grade serous carcinoma from the fallopian tube. Gynecologic Oncology, Volume 141, Supplement 1, June 2016, Page 56.
9. Forde B, Wallbillich JJ, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer: A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic Oncology, Volume 137, Supplement 1, April 2015, Page 24.
10. Wallbillich JJ, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz MM, Brown J, Schmeler KM. Vulvar Intraepithelial Neoplasia (VIN2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology, Volume 125, Supplement 1, March 2012, Page s82.
11. Costales AB, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, Frumovitz MM, Schmeler, KM. Residual disease and invasive carcinoma in women undergoing hysterectomy for adenocarcinoma in situ (AIS) of the cervix. Gynecologic Oncology, Volume 125, Supplement 1, March 2012, Page s53.
12. Meyer L, Schmeler K, Wallbillich J, Urbauer D, Soliman P, Frumovitz M, Burke C, Bodurka D, Levenback C. Clinical Practice Guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. Gynecologic Oncology, Volume 120, Supplement 1, March 2011, Pages s30-s31.
Presentations
Podium Presentations (refereed)
1. Griswold L*, Williams H, Patel K, Bailey C, Swartz S, Burchett K, Wallbillich J, Ghamande S, Rungruang B. (October 2018). A review of disparities and their impact on survival in vulvar cancer. *Oral presentation given at: Mid-Atlantic Gynecologic Oncology Society Annual Meeting, Columbus, OH, October 2018.
2. Patel KB*, Pyrzak A, Williams H, Coste H, Zhang LF, Sadek R, Wallbillich JJ, Ghamande S, Rungruang BJ. Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. *Scientific Plenary presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, New Orleans, LA, March 2018.
3. Forde B*, Wallbillich JJ, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer: A cost utility analysis of genomic-based versus cytotoxic therapy. *Scientific Plenary presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Chicago, IL, March 2015.
Poster Presentations (refereed)
1. Myers E*, Tran LK*, Tran PM, Mysona D, Purohit S, Wallbillich JJ, She JX. Identifying genetic drivers of uterine serous carcinoma patient prognosis with regulatory network analysis. *Poster presented at: American Association for Cancer Research Annual Meeting, Atlanta, GA, March 2019.
2. Tran LK*, Myers EK, Mysona DP, Tran PM, Lee W, Wallbillich JJ, Kleven D, Ghamande S, She JX. Predicting survival and improving treatment for uterine serous carcinoma patients using USC78, a genomic risk score. *Poster presented at: American Association for Cancer Research Annual Meeting, Atlanta, GA, March 2019.
3. Purohit S*, Tran PMH, Tran LKH, Zhi W, Song X, Dun B, Ferris DG, Wallbillich JJ, Cummings RD, Wang PG, She JX. Anti-glycan antibodies as predictors of therapeutic outcome in cervical cancer patients. *Poster presented at: American Association for Cancer Research Annual Meeting, Atlanta, GA, March 2019.
4. Williams HR, Patel K, Bailey C, Zhang LF, Sadek R, Wallbillich J, Ghamande S, Rungruang B. No impact of race on the survival of patients with uterine carcinosarcoma. *Poster presented at: Mid-Atlantic Gynecologic Oncology Society Annual Meeting, Columbus, OH, October 2018.
5. Pyrzak A*, Patel KB, Williams H, Coste H, Zhang LF, Sadek R, Wallbillich JJ, Ghamande S, Rungruang BJ. Clinical trial participation may improve survival in patients with advanced epithelial ovarian, fallopian, and peritoneal malignancies. *Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, New Orleans, LA, March 2018.
6. Dorayappan KDP*, Zingarelli RA, Hisey CL, Smith BQ, Wanner R, Saini U, Hansford D, Wallbillich JJ, She JX, Lester J, Karlan BY, Suarez A, Cohn DE, Karuppaiyah S. Evaluating exosome proteins as biomarkers for the early detection of high-grade serous ovarian cancer. *Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, New Orleans, LA, March 2018.
7. Saini U, Bixel K, Wallbillich JJ*, Riley MK, Fowler J, Wanner R, Lester J, Karlan BY, Goodfellow PJ, Suarez A, Cohn DE and Selvendiran K. STAT3/PIAS3 as “early signature” gene pathways in the development of ovarian high grade serous carcinoma from the fallopian tube. *Featured Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, San Diego, CA, March 2016.
8. Dorayappan KDP, Wallbillich JJ*, Saini U, Bixel K, Riley MK, Zingarelli RA, Wanner RA, Goodfellow PJ, Cohn DE, Selvendiran K. Hypoxia-facilitated exosomal release from ovarian cancer cells is regulated by STAT3 and is associated with increased metastatic tumor burden. *Featured Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, San Diego, CA, March 2016.
9. Costales AB*, Milbourne AM, Rhodes HE, Munsell MF, Wallbillich JJ, Brown J, Frumovitz MM, Schmeler, KM. Residual disease and invasive carcinoma in women undergoing hysterectomy for adenocarcinoma in situ (AIS) of the cervix. *Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Austin, TX, March 2012.
10. Wallbillich JJ*, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz MM, Brown J, Schmeler KM. Vulvar Intraepithelial Neoplasia (VIN2/3): comparing clinical outcomes and evaluating risk factors for recurrence. *Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Austin, TX, March 2012
11. Meyer L*, Schmeler K, Wallbillich J, Urbauer D, Soliman P, Frumovitz M, Burke C, Bodurka D, Levenback C. Clinical Practice Guidelines decrease unnecessary Pap tests in survivors of gynecologic malignancies. *Featured Poster presented at: The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Orlando, FL, March 2011.
12. Meyer L*, Levenback C, Wallbillich J, Garcia E, Urbauer D, Soliman P, Frumovitz M, Burke C, Schmeler K. The Proper Pap: Reducing the Overutilization of Pap Test for Disease Surveillance in Survivors of Gynecologic Malignancies. *Poster presented at: The University of Texas System Clinical Safety and Effectiveness Conference, Austin, TX, November 2010.
13. Wallbillich J*, Angulo-Barroso R, Streepey, J. The Impact of Vision and Foot Pressure Sensor Input on Balance Control in Children and Adults. *Poster presented at: The National Conference on Undergraduate Research; Salt Lake City, UT, March 2003.
Other
1. Wallbillich JJ*, Tran P, Tran L, Bai S, Sharma A, Meyers E, Rungruang B, Macfee M, Ghamande S, She JX. Genomic risk of mortality in squamous cell cervical cancer. *Oral presentation given at: Women’s Reproductive Health Research (WRHR) National Symposium, Seattle, WA, November 2018.
2. Wallbillich JJ*, Tran P, Bai S, Li S, Sharma A, She JX. Genomic risk for mortality in squamous cell cervical cancer. *Oral presentation given at: Women’s Reproductive Health Research (WRHR) National Symposium, Chicago, IL, November 2017.
3. Wallbillich JJ*, Bai S, Sharma A, She JX. From Big Data to Bench to Bedside: Building a Genomic-Guided Pipeline for Novel Combination Therapies against Gynecologic Cancer. *Oral presentation given at: Women’s Reproductive Health Research (WRHR) Retreat, Augusta, GA, December 2016.
4. Wallbillich JJ*, Josyula S, Saini U, Zingarelli RA, Dorayappan KDP, Riley MK, Wanner RA, Cohn DE, Selvendiran K. High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: novel therapeutic implications for endometrial cancer. *Poster presented at: The Ohio State University Comprehensive Cancer Center – James Annual Scientific Meeting, Columbus, OH, April 2016.
Other Information
Invited lectures/presentations
Distillation of Scientific Session III, Endometrial Cancer. Presented at: Mid-Atlantic Gynecologic
Oncology Society Annual Meeting, October 26, 2018. Columbus, OH.